U.S. markets close in 1 hour 27 minutes

Siemens Healthineers AG (SMMNY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
29.19+0.92 (+3.25%)
As of 2:09PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close28.27
Bid0.00 x 0
Ask0.00 x 0
Day's Range28.99 - 29.22
52 Week Range25.74 - 30.90
Avg. Volume45,875
Market Cap65.842B
Beta (5Y Monthly)0.46
PE Ratio (TTM)32.29
EPS (TTM)0.90
Earnings DateN/A
Forward Dividend & Yield0.48 (1.70%)
Ex-Dividend DateFeb 12, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PTC Set to Join S&P 500; Lattice Semiconductor & Progyny to Join S&P MidCap 400; Domtar to Join S&P SmallCap 600
    PR Newswire

    PTC Set to Join S&P 500; Lattice Semiconductor & Progyny to Join S&P MidCap 400; Domtar to Join S&P SmallCap 600

    S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the open of trading on Tuesday, April 20:

  • Varian Announces CEO Succession Plan
    PR Newswire

    Varian Announces CEO Succession Plan

    Varian (NYSE: VAR) today announced that Chief Executive Officer Dow Wilson, after more than 16 years with the Company, will retire upon the successful completion of the proposed combination of Varian and Siemens Healthineers AG (Frankfurt: SHL). Wilson will be succeeded by Chris Toth, President and Chief Operating Officer of Varian, who will become CEO of the Varian business segment of Siemens Healthineers upon the transaction close. Toth will report directly to Dr. Bernd Montag, Chief Executive Officer of Siemens Healthineers.

  • Siemens Healthineers’ $16.4B Takeover Of Varian To Win EU Clearance – Report

    Siemens Healthineers’ $16.4B Takeover Of Varian To Win EU Clearance – Report

    Siemens Healthineers’ $16.4 billion purchase of Varian Medical Systems is likely to get conditional clearance from EU antitrust regulators, Reuters has learnt. The clearance comes after Siemens Healthineers last month offered concessions to address competition concerns regarding interoperability, according to the report. The European Commission is scheduled to decide on the deal by Feb. 19. Varian (VAR) announced the $16.4 billion takeover by Siemens in August last year. According to the terms of the agreement, Siemens Healthineers offered to pay $177.50 per share in cash for all outstanding shares of Varian. This represented a 42% premium to the 30-day volume weighted average closing price of Varian’s shares as on July 31, 2020. The acquisition seeks to create a multi-disciplinary healthcare company with a comprehensive cancer care portfolio. The transaction is expected to close in the first half of this year. In October last year, Varian shareholders had also approved the transaction. Varian is a developer of oncology care technologies and solutions while Siemens Healthineers is a medical technology company whose portfolio includes imaging and diagnostic systems and advanced therapy systems including angiography systems and computed tomography (CT) systems. (See Varian Medical Systems stock analysis on TipRanks) Late last month, Barrington Research analyst Michael Petusky reiterated a Sell on Varian stock. Petusky commented on the acquisition, “…these two businesses appear highly complementary and will establish an integrated platform of end-to-end oncology solutions from front-end screening and diagnosis to the delivery of care and post-treatment survivorship. It is worth mentioning that Varian will continue to operate under the Varian brand name given its strength in the marketplace it serves.” The rest of the Street is cautiously bearish about the stock with a Moderate Sell consensus rating. That’s based on 2 analysts recommending a Hold and 1 analyst suggesting a Sell. The average analyst price target of $178 implies 1.07% upside potential to current levels. Related News: Nissan Denies Talks With Apple Over Autonomous Car Venture – Report Google Clinches Content Licensing Deal With Australia’s Seven West Microsoft Showed Interest In Pinterest Takeover – Report More recent articles from Smarter Analyst: Google Clinches Content Licensing Deal With Australia’s Seven West BP Ties Up With IBM’s Quantum Network NextEra Energy Ramps Up Quarterly Dividend By 10%; Street Says Buy Lanxess Inks $1.08B Deal To Snap Up Emerald Kalama Chemical